INTRODUCTION
Human blood plasma is an attractive biomaterial source for clinical diagnosis, since it is easily obtained through minimally invasive procedures and because many disease states produce changes in blood biomolecules. Indeed, better clinical diagnostics have been widely anticipated from application of proteomic technologies to analyze plasma proteomes 1 . A principal barrier to realizing this goal is the wide dynamic range of human plasma protein concentrations, which is thought to exceed ten orders of magnitude. The 22 most abundant proteins in human plasma comprise ~99% of the total protein mass, while lower abundance proteins derived from tissue secretion and leakage are typically present at concentrations in the nanogram per milliliter range and in combination do not make up more than 1% of the plasma protein mass 1 . Hence, depletion of these major proteins is one potential strategy for improving proteomic analyses of plasma. Abundant protein depletion has been applied mainly to increase the breadth and depth of proteome identifications in unbiased discovery, but depletion also can increase sensitivity for targeted analyses of specific proteins.
Published work describes a variety of methods to remove high abundance proteins from plasma and serum (for a review, see Pernemalm 2 ). The lipophilic dye Cibacron blue was introduced to facilitate albumin purification 3 and then adapted to albumin depletion for proteomics 4, 5 . Similarly, Protein A or G can selectively deplete immunoglobulins 6, 7 . Pieper and colleagues provided a key conceptual advance by employing multiple immobilized antibodies to deplete high abundance proteins from plasma 8 . This approach is now available through over a dozen commercially-available products 2 .
Among the most widely used products (based on literature citations) is the Multiple Affinity Removal System (MARS † ; Agilent Technologies, Santa Clara, CA), which offers removal of 7 (MARS-7) or 14 (MARS-14) abundant plasma proteins. An earlier product (MARS-6) sold prior to 2008 was directed at 6 abundant proteins. Our interest in the MARS-7
and MARS-14 columns is due in large part to the adoption of this system for abundant plasma protein depletion in ongoing interlaboratory studies by the National Cancer Institute Clinical Proteomic Technologies Assessment for Cancer (CPTAC) program, in which we are participants.
Several previous reports have characterized the performance of the MARS-6 or MARS-7
columns for abundant protein depletion in analyses of plasma and serum. Of these, 5 used twodimensional sodium dodecyl sulfate-polyacrylamide gel electrophoresis to analyze the low abundance protein fraction [8] [9] [10] [11] [12] . These studies yielded limited proteome inventories (<100 protein identifications) and provided an essentially qualitative assessment of the impact of depletion on detection of plasma and serum proteins.
Two more recent studies 13, 14 employed liquid chromatography-tandem mass spectrometry (LC-MS/MS) to generate larger proteome inventories (>200 protein identifications).
The primary metric for assessing the impact of high abundance protein depletion in both studies was increased numbers of proteins detected. Whiteaker et al. 13 also reported increased coverage of some proteins in the depleted samples, whereas Gong et al. 14 reported detection of 10 lowabundance proteins (concentrations <100 ng mL -1 based on literature annotations) only in depleted samples. The only quantitative assessment of enhanced detection of low abundance proteins as a result of MARS depletion was reported by Brand et al., who reported ELISA measurements on 11 proteins 15 . We note that other publications report the use of MARS columns in sample preparation for proteome analyses, but did not specifically evaluate the impact of this step (e.g., 16, 17 ).
The available literature indicates that abundant protein depletion using the MARS system enhances detection of lower abundance proteins, but the impact has not been characterized on a global proteomic scale. Moreover, previous reports did not assess the reproducibility of the depletion step or the degree to which non-target proteins were captured by the MARS columns.
Most of these aspects were characterized, however, in recent studies of the IgY-14 and the Seppro SuperMix products (Genway, San Diego, CA), which deplete either 14 or more than 50 high abundance plasma proteins, respectively [18] [19] [20] . In light of the widespread use of the MARS system, the somewhat limited quantitative characterization of its performance in previous studies, and the planned use of MARS columns in CPTAC studies, we felt that a detailed characterization of this system was justified.
One striking characteristic of plasma proteome datasets is the relatively small number of proteins identified in comparison to analyses of cells or tissues. Application of one dimensional LC-MS/MS, together with commonly accepted criteria for protein identification (≥ 2 peptides at <5% false discovery rate (FDR)) yielded approximately 150-250 proteins 13, 20 , whereas addition of multidimensional LC-MS/MS yielded 200-700 proteins 14, 20 . Even the multilaboratory HUPO plasma proteome study yielded less than 900 high confidence protein identifications 21 . These totals are approximately 2-5-fold less than have been reported for analyses of cell and tissue extracts using similar protein input amounts and similar LC-MS/MS platforms [22] [23] [24] [25] [26] . Although this effect is commonly attributed to the overwhelming predominance of a small number of high abundance proteins, this disparity has not been explored with both tissue and plasma proteomes in the same experimental system.
Here we present a detailed evaluation of the MARS-7 and MARS-14 systems in the analysis of human plasma by shotgun proteomics using 
MATERIALS AND METHODS

Plasma samples
Human blood plasma samples were obtained from three anonymous healthy volunteers 
MARS-7 and MARS-14 immunoaffinity chromatography
MARS-7 columns (4.6 x 100 mm) designed to deplete 7 abundant proteins (albumin, IgG, antitrypsin, IgA, transferrin, haptoglobin, fibrinogen) and MARS-14 columns (4.6 x 100 mm) designed to deplete 14 abundant proteins (albumin, IgG, antitrypsin, IgA, transferrin, haptoglobin, fibrinogen, alpha2-macroglobulin, alpha1-acid glycoprotein, IgM, apolipoprotein AІ, apolipoprotein AII, complement C3, and transthyretin) were purchased from Agilent (Palo Alto, CA). Depletion was performed at room temperature with an Agilent 1100 series HPLC system. Plasma samples were diluted fourfold using the load/wash buffer supplied by the manufacture and remaining particulates in the diluted plasma were removed by centrifugation through a 0.22-μm spin filter 1 min at 16,000 × g.
After equilibration with the load/wash buffer, the MARS-7 column was loaded with 160 μL of the diluted plasma at a low flow rate (0.5 mL min 
Protein Digestion
The depleted and bound protein fractions prepared from each sample were concentrated using Amicon 5 KDa molecular weight filters (Millipore, MA), followed by buffer exchange to 50 mM NH 4 HCO 3 in the same unit. Protein concentration was then determined by the BCA protein assay (Pierce-Thermo Scientific, Rockford, IL). Proteins were denatured and reduced in 50 mM ammonium bicarbonate buffer, pH 8.0, 8 M urea, 10 mM dithiothreitol for 1 hour at 37 °C. Protein cysteines were alkylated with 50 mM iodoacetamide for 60 min at room temperature in the dark. The reduced and alkylated protein mixture was diluted 10-fold with 50 mM ammonium bicarbonate, pH 8.0, followed by the addition of trypsin (Promega, Cat#TB309, Madison, WI) at a trypsin/protein ratio of 1:50 (w/w). The digestion mixture was incubated overnight at 37 °C and then frozen at -80 °C and lyophilized. Samples were resuspended in 1 mL of deionized water and applied to SEP-Pak vac 1 cc (100 mg) C-18 cartridges (Waters Corp., Milford, MA), which were prewashed with 1 mL of acetonitrile and equilibrated with 2 mL of deionized water. The flow-through was discarded, the cartridges were washed with 1 mL of deionized water, the bound peptides were eluted with 80% acetonitrile in deionized water, and the eluate was evaporated in vacuo.
IEF of peptides
Tryptic peptides from 200 μg of protein were redissolved in 500 μL of 6 M urea and loaded in an IPGphor rehydration tray (GE Healthcare, Piscataway, NJ). Carrier ampholyte (2% (v/v) was included in the loading solution (IPG buffer pH 3-10 NL (GE catalog #17-6000-88)).
IPG strips (24 cm, pH 3-10 NL) (GE Healthcare) were placed over the samples and allowed to rehydrate overnight at room temperature. The loaded strips were focused at 20 °C on an Ettan
IPGPhor-III IEF system (GE Healthcare) using the following focusing program: 500 V for 1 hr; a gradient to 1000 V for 3 hr; a gradient to 10000 V for 3 hr; a step to 10000 V for 5 hr. The MS/MS analysis, as previously described 24 .
Reverse-phase LC-MS/MS analysis
LC-MS/MS analyses were performed on a Thermo LTQ linear ion trap mass spectrometer equipped with a Thermo MicroAS autosampler and Thermo Surveyor HPLC pump, Nanospray source and Xcalibur 1.4 instrument control (Thermo Electron, San Jose, CA).
Peptides were separated on a packed capillary tip (Polymicro Technologies, 100 μm X 11 cm)
with Jupiter C18 resin (5 μm, 300 Å, Phenomenex) using an in-line solid-phase extraction column (100 μm X 6 cm) packed with the same C18 resin (using a frit generated with liquid silicate Kasil 1 27 ) similar to that previously described 28 . The flow from the HPLC pump was split prior to the injection valve to achieve flow-rates of 700 nL-1000 μL min-1 at the column tip.
Mobile phase A consisted of 0.1 % formic acid and Mobile phase B consisted of 0.1% formic acid in acetonitrile. A 95 min gradient was performed with a 15 min washing period (100 % A for the first 10 min followed by a gradient to 98% A at 15 minutes) to allow for solid-phase extraction and removal of any residual salts. Following the washing period, the gradient was increased to 25% B by 50 min, followed by an increase to 90 % B by 65 min and held for 9 min before returning to the initial conditions. Liquid chromatography was carried out at ambient temperature at a flow rate of 0.6 μL min -1 . Centroided MS/MS scans were acquired on the LTQ using an isolation width of 2 m/z, an activation time of 30 ms, an activation q of 0.250 and 30% normalized collision energy using 1 microscan with a max ion time of 100 ms for each MS/MS scan and 1 microscan with a max ion time of 500 ms for each full MS scan. The mass spectrometer was tuned prior to analysis using the synthetic peptide TpepK (AVAGKAGAR), so that some parameters may have varied slightly from experiment to experiment, but typically the tune parameters were as follows: spray voltage of 2 kV, a capillary temperature of 150 °C, a capillary voltage of 50 V and tube lens of 120 V. The MS/MS spectra were collected using datadependent scanning in which one full MS spectrum was followed by four MS-MS spectra.
MS/MS spectra were recorded using dynamic exclusion of previously analyzed precursors for 60 s with a repeat count of 1 and a repeat duration of 1.
Data processing and analysis
The LC-MS/MS raw data were converted into mzData file format by ScanSifter v2.0, an in-house developed software, and the MyriMatch algorithm (version 1. Candidate peptides were required to feature semitryptic cleavages, which allow one non-tryptic end, and any number of missed cleavages was permitted. Carbamidomethylation of cysteines was specified as a fixed modification, and variable modifications of methionine oxidation, Nterminal pyro-Glu from glutamine were allowed during the database search. The sequence database was doubled to contain each sequence in both forward and reversed orientations, enabling false discovery rate estimation.
The IDPicker algorithm 30 (version XXX) filtered the identifications for each LC-MS/MS run to include the largest set for which a 5% peptide identification FDR could be maintained.
These identifications were pooled for each sample. The peptide filtering employed reversed sequence database match information to determine thresholds that yielded an estimated 5% FDR for the identifications of each charge state by the formula FDR = (2 × reverse) / (forward + reverse) 31 . Proteins were required to have at least two distinct peptide sequences observed in the analyses. Indistinguishable proteins were recognized and grouped. Parsimony rules were applied to generate a minimal list of proteins that explained all of the peptides that passed our entry criteria 30 .
Relative peptide/protein intensity analysis
Relative peptide intensities were calculated in the following way. First, MS/MS spectra were extracted to MGF files using ReAdWRaw4Mascot.exe (version 20091016a) and identified
by searching the NIST library of peptide fragmentation mass spectra (Human IT Rel. 3, 02/04/09) with MSPepSearch (Version 0.9, NIST), both were downloaded from http://peptide.nist.gov.
Mass tolerances were set to 0.7 m/z and 0.8 m/z for precursor and fragment masses, respectively.
Additionally, MSPepSearch was set to pre-search all spectra in fast, peptide mode (fiPv), and all top-ranked matches were filtered to a 'Score' threshold of >450 (<1% FDR according to previous decoy searches, data not shown). Then, for each identified peptide ion, the maximum abundance was estimated from extracted ion chromatograms (also with ReAdW4Mascot.exe).
Relative peptide intensity was then calculated as the fraction of all peptide intensity values for each peptide. To calculate relative protein intensity values, proteins were reassembled by first mapping the peptides to protein sequences. Only proteins with more than one distinct peptide sequence were counted and peptide intensities were assigned to only one protein. When several proteins contained a given sequence, assignment was made to the protein having the largest number of assigned peptides. Peptide ion intensities for each protein then were summed and the relative abundance for each protein was calculated as the fraction of all protein abundances.
RESULTS
Sample recoveries and repeatability for MARS-7 and MARS-14 column separations
Three separate samples of human plasma (3.3 mg plasma protein each) were fractionated with MARS-7 and MARS-14 columns and recoveries were determined for both the flow-through and bound fractions (Table 1 ). An average of 0.40 mg (12%) and 2.09 mg (63%) of applied protein was recovered from the MARS-7 flow-through and bound fractions, respectively. From the MARS-14 an average of 0.25 mg (8%) and 2.23 mg (68%) of the applied protein was recovered from the flow-through and bound fractions, respectively (Table 1) . CV values for recoveries of proteins from the flow-through and bound fractions across the three replicates were between 2 and 6%, indicating overall repeatability of the analysis. Ultraviolet detection (220 nm)
traces for each run demonstrated consistent chromatography for both the MARS-7 column and MARS-14 column ( Figure S1 ).
Analysis of MARS-7 and MARS-14 plasma protein fractions by LC-MS/MS
We evaluated the repeatability of MARS-7 and MARS-14 using the same plasma sample and reverse phase LC-MS/MS. Separations with the MARS-7 and MARS-14 were done three times and the corresponding flow-through and bound fractions were individually analyzed. A total of 43, 36 and 40 proteins were identified from the MARS-7 bound fractions and 107, 106
and 99 proteins were identified from flow-through fractions, respectively. Not included in these totals are many spectral matches to a large number of different immunoglobulin sequences; the extensive sequence overlap between these database entries made it impossible to discern the total number of proteins present based on peptide identifications. A total of 52, 52 and 50 proteins were identified from the MARS-14 bound fraction and 114, 118 and 113 proteins were identified from flow-through fraction, respectively. As for the MARS-7 analyses, spectral matches to immunoglobulins were excluded.
The numbers of proteins identified in the triplicate analyses were largely consistent in both fractions from each column. We used spectral count data for quantitative comparisons, as this method provides robust estimates of differential protein concentrations in shotgun proteomic analyses 32, 33 . An illustration of the consistency of proteome inventories based on spectral counting is shown in Figure 1 . respectively, indicating that spectral counts for the large majority of proteins proved highly reproducible across replicate depletion experiments using the MARS system.
Efficiency of high abundance protein depletion by MARS-7 and MARS-14 columns
The premise of the MARS system is that enrichment of lower abundance proteins can be achieved through efficient extraction of high abundance proteins by the column. We measured efficiency of high abundance protein extraction on the basis of spectral counts from LC-MS/MS analyses of bound and flow-through fractions from three replicate MARS-7 or MARS-14 depletions. Although the bound and flow-through proteins are different in peptide composition, the spectral count data still allowed us to identify those proteins that are efficiently captured by the columns. The binding efficiency was calculated for each protein by dividing the spectral counts for each protein from the bound fraction (B) by the sum of spectral counts from the bound fraction and flow-through fraction (FT), i.e. B/(B+FT) 19 . In this study, albumin, IgG, antitrypsin, MARS-14 column, as shown in 
Binding of non-target plasma proteins to MARS-7 and MARS-14 columns
A potential problem with immunoaffinity protein depletion is that some non-target proteins might be removed along with the targeted proteins, either because they associate with target proteins or because they nonspecifically interact with the column. We refer to these as Table S1 .) Several of the higher abundance non-target proteins bound to the MARS-7 column are target proteins for the MARS-14 column (α-2 macroglobulin, apolipoprotein AI, α1-acid glycoprotein 1, α1-acid glycoprotein 2, and transthyretin). Others were consistently detected only as non-target proteins on MARS-14 columns (pregnancy zone protein, apolipoprotein B-100, apoliproprotein CII, apolipoprotein CIII). Of the proteins we detected as having significant non-target binding to the MARS columns, CD5 antigen-like protein, zinc-α 2 -glycoprotein, hemoglobin, apolipoprotein C-III, apolipoprotein L1 and serum amyloid A-4 protein also were reported as non-target proteins for the IgY12 column 19 .
Impact of high-abundance protein depletion on detection of lower abundance proteins
We used multidimensional LC-MS/MS to evaluate the extent to which lower abundance proteins could be detected in depleted versus undepleted plasma. The same quantities of peptides from unfractionated plasma, the MARS-7 FT fraction and the MARS-14 FT fraction were resolved by IEF into 20 fractions prior to LC-MS/MS. Only those proteins identified with at least two unique peptides from the entire study set were considered confident identifications.
(The full IDPicker report, which contains an .html summary of all identified peptides and proteins is supplied as Supplementary Information.)
Additionally, we filtered out all proteins that had less than 10 spectra identified in the Spectral count data provide a robust means to estimate protein abundances from shotgun proteomic datasets 32, 33 . Figure 4 illustrates the rank correlation (r 2 = 0.921) between the spectral counts for 100 proteins detected in crude plasma and with previously reported protein concentrations in plasma. We compared the spectral counts for proteins detected in the MARS FT fractions to the counts for the same proteins in crude plasma. Only the 100 proteins observed with at least 10 spectral counts in the entire study were used and these were ranked by spectral counts in the crude plasma. (The immunoglobulin identifications were excluded). To assess the level of enrichment for lower abundant proteins, the log 2 of the ratio of counts in the MARS FT fraction to crude (unfractionated) plasma was used to estimate the increase (or decrease) in detection as a function of MARS fractionation ( Figure 5 ). For proteins detected only in MARS FT fractions, the denominator of the ratio is zero; thus, for these proteins a single count was used.
A positive log 2 ratio means that the spectral counts for the protein are higher in MARS flowthrough than in crude plasma.
Analysis of the MARS-7 FT indicated that 205 proteins (95% of the total detected)
increased in spectral counts by at least 2-fold compared to unfractionated plasma ( Figure 5 ).
Similarly, in the MARS-14 FT, 193 proteins (94% of the total detected) increased the spectral counts by at least 2-fold. For both the MARS-7 and MARS-14 columns, enrichment relative to undepleted plasma ranged from 2-4 fold. Figure 5 also illustrates the depletion of some proteins by the MARS-7 and MARS-14 columns; these include the target proteins and some non-target proteins described above and listed in Table 2 and Figure 2 .
Among the proteins with enhanced detection in the MARS-7 and MARS-14 FT fractions
were 23 proteins present at plasma concentrations of 10 ng mL -1 or lower Table S4 .
Concentrations for these proteins were obtained from previously reported data for plasma or serum levels in normal human subjects 1 . These very low abundance proteins accounted for only 5.6% and 6.0% of the proteins detected in the MARS-7 and MARS-14 FT fractions, respectively.
Comparison of protein identifications between crude plasma, depleted plasma and RKO cells
Analysis of undepleted plasma and the MARS-7 and MARS-14 depleted plasma by IEF-LC-MS/MS collectively yielded 659 protein identifications (with at least 2 identified peptides).
This total was significantly lower than we had identified in analyses of human colon adenomas and tumor cells with a similar IEF-LC-MS/MS platform 24, 25 . To compare these proteomes in the same analysis, we analyzed 200 μg of protein each from RKO colon tumor cells, from unfractionated plasma and from the MARS FT fractions. The analyses were done in three replicates each with the IEF-LC-MS/MS platform described above. We confidently identified 3411 proteins in RKO cells, 371 proteins from unfractionated plasma, 342 proteins in MARS-7 depleted plasma and 288 proteins in MARS-14 depleted plasma. Our analyses of IEF fractions from undepleted plasma acquired 287,223 MS/MS spectra, which is nearly identical to the total acquired (289,010 spectra) in analysis of RKO cells.
We hypothesized that protein identifications in plasma may be diminished by significant numbers of peptides (e.g., variant immunoglobulin sequences) that are not represented in the search database and thus cannot be identified by database searching. If so, we reasoned that addition of plasma to the RKO cell lysate might decrease the number of spectral counts for RKO protein without producing a concomitant increase in plasma protein spectral counts.
We performed a plasma spike experiment, in which the total amount of plasma and RKO cell protein mixture was fixed. We spiked 0, 1%, 2%, 5%, 10%, and 20% plasma protein into RKO cell lysates to create 7 mixed samples; we also prepared a 100% plasma sample ( Figure 6 ).
All were analyzed by reverse phase LC-MS/MS (no IEF). "Confident IDs" refers to MS/MS spectra mapped to peptides according to the criteria described in Experimental Procedures (see above). Proteins found only in unspiked RKO cell lysates were assumed to be derived only from RKO cells, whereas other proteins were assumed to be derived from plasma. Identifications either in RKO lysates or in plasma comprised "total confident IDs" and "total proteins" in Figure   6 . All of the analyses yielded essentially identical numbers of MS/MS spectra. Numbers of confidently identified RKO peptides did not decrease with increasing plasma spike concentration, nor did total numbers of identified peptides. Similar results were obtained for identifications at the protein level. Nevertheless, the sample containing 100% plasma yielded many fewer protein identifications than the RKO lysate and the RKO/plasma mixtures. These data suggest that lower numbers of plasma protein identifications reflects the presence of unidentifiable peptide sequences not represented in the database.
Impact of protein abundance distribution on proteome analyses
A characteristic feature of the plasma proteome is the high concentration of a few dozen blood proteins, which comprise approximately 99% of total plasma protein 1 . This fact provides the driving rationale for immunodepletion strategies, but it is not clear whether it also explains the disparity in proteome inventories from plasma and cells. Cells also display a broad range of protein abundances 34, 35 , which could similarly affect detection of lower abundance proteins.
We reasoned that any bias due to oversampling of highly abundant peptides would be evident in spectral count data for the detected peptides and proteins. Plots of protein order as a function of spectral counts for RKO cells, undepleted plasma, MARS-7 FT, and MARS-14 FT proteomes are shown in Figure 7 . In each plot, the spectral count curve for detected peptides and proteins is considerably steeper for plasma and the MARS FT fractions than for RKO cells. For example, the (blue) curve for plasma in Figure 7A shows that the top 10 proteins account for 70% of the spectral counts, whereas the curve for RKO cells shows that the top 10 proteins account for less than 205 of the total. These relationships are consistently observed in plots where spectral counts for multiple peptides are combined to generate protein spectral counts ( Figures 7A and 7B) or when spectral counts for individual peptides are plotted ( Figures 7C and 7D ). These 
DISCUSSION
Depletion of abundant plasma proteins with immunoaffinity columns was originally applied in the context 2D gel analyses to observe changes in the lower abundance proteome that were literally obscured by high abundance proteins 8 . Subsequent work confirmed the ability of abundant protein depletion to facilitate detection of lower abundance plasma and serum proteins 2 . However, much of this work was done with older proteomic technologies (i.e., 2D gels) and did not involve quantitative assessment of either protein depletion or the enhanced detection of lower abundance proteins. We undertook our study to quantitatively assess the performance of the MARS system with a current generation LC-MS/MS analysis platform. Our results demonstrate that the MARS-7 and MARS-14 systems provide largely specific and highly repeatable depletion of their target proteins in human plasma and that they broadly enhance detection of plasma proteins by 2-4 fold. Our studies also highlighted the disparity in protein identifications between plasma and cell proteomes. This disparity is due to the uniquely steep concentration curve for plasma proteins. The results further imply that shotgun proteomic analysis of plasma is poorly suited to discover low abundance proteins as candidate disease biomarkers, even in samples depleted of the most abundant proteins.
The MARS-7 and MARS-14 columns displayed consistent performance in depleting target proteins, although not all targets were captured with equal efficiency. Albumin, IgG, antitrypsin, IgA, transferrin and haptoglobin were captured with >99% efficiency both by the MARS-7 and MARS-14 column and as previously reported for the MARS-6 column 15 .
Fibrinogen was captured only with 71% and 76% efficiency by MARS-7 and MARS-14, respectively. Apolipoprotein AI and apolipoprotein AII were captured only with 47% and 31%
efficiency by the MARS-14 column (these proteins were not targeted by the MARS-7 column).
In addition to consistently depleting target proteins and causing minimal depletion of non-target proteins, the MARS columns broadly enhanced detection of plasma proteins, typically by 2-4-fold, based on spectral counts. In our IEF-LC-MS/MS analyses MARS immunodepletion typically increased detection of plasma proteins by 30-40% relative to non-depleted plasma.
Although the MARS-14 column removed 7 additional proteins and a greater fraction of the plasma proteome mass, this conferred no real advantage over the MARS-7 column in enhancing global plasma protein identifications-indeed, the MARS-14 FT fraction yielded slightly fewer identifications (208 vs. 216) than the MARS-7 FT. Our data and that of Qian et al. 20 demonstrate increased detection of several plasma proteins with reported concentrations <10 ng mL -1 . Nevertheless, it appears that these increased detections represent exceptions to the rule that proteins at concentrations below μg mL -1 are sporadically detected in shotgun proteome analyses, even in immunodepleted plasma 21, 36 .
A frequently expressed concern regarding immunodepletion strategies is the removal of non-target proteins through non-specific association with the depletion columns or with captured
proteins. This has been described as the "albumin sponge effect" 37, 38 . We observed that the bound fraction associated with MARS-7 and MARS-14 columns contained 30 non-target proteins, most of which were captured at low levels based on spectral counts (Table S3 ). This finding is similar to the previous report of 38 non-target proteins captured by IgY-12 columns 19 .
For those non-target proteins captured at higher levels, binding appeared to be reproducible ( Figure 2 ). We note that specific interaction with target proteins may explain at least a few of the non-target captures. For example, hemoglobin is reported to bind to haptoglobin and zinc-α 2 -glycoprotein may interact with the targeted apolipoproteins and interact directly with the Fc region of IgG 39, 40 . Pregnancy zone protein, a relatively abundant pregnancy-associated plasma protein, has strong similarity to alpha-2-macroglobulin 41 , which perhaps explained why pregnancy zone protein was only captured by the MARS-14 column (which captures alpha-2-macroglobulin), but not by the MARS-7 column. Our observations regarding non-target protein capture are similar to those reported by Qian et al. 20 , who performed similar evaluation of the IgY14 and SuperMix columns. Taken together, these observations with two widely used products suggest that inadvertent capture of non-target proteins is unlikely to interfere with the performance of analysis platforms that incorporate an abundant plasma protein depletion step.
Beyond the characterization of the MARS columns for enhancement of plasma proteome analysis, our second major goal was to address reasons for the dramatic disparity in protein identifications between plasma and cell proteomes. Given identical protein input and analysis on a standardized IEF-LC-MS/MS platform, the difference in identifications between plasma and cell lysates was striking-nearly 10-fold. We recognized that the presence of a relatively small number of highly abundant proteins has long been recognized as a barrier to plasma proteome analysis, but we considered other possible contributing factors. First, IEF-LC-MS/MS analyses of plasma, MARS-depleted plasma and RKO cells all yielded comparable numbers of MS/MS spectra. Our mixing experiments with plasma and RKO cell lysates tested the hypothesis that some components of plasma proteomes (e.g., uncharacterized immunoglobulin sequences) suppressed protein detection by generating MS/MS spectra that could not be matched to database sequences. These experiments showed that the decrement in detected RKO proteins resulting from plasma spikes was no more than would be expected based on simple competition from identifiable plasma proteins. These experiments don't eliminate the possibility that unidentified protein and peptide sequences are present in plasma, but do suggest that they do not significantly suppress protein detection or identification.
Our final experiments compared the quantitative hierarchy of plasma, depleted plasma and cell lysate proteomes based on spectral counts and MS1 signal intensities. Both analyses clearly demonstrated that plasma and immunodepleted plasma fractions display a much steeper concentration curve for the most abundant proteins. This steep abundance curve appears to be the major reason for the low numbers of plasma protein identifications. We note that in our analyses of the 100% plasma sample shown in Figure 6 , numbers of confident peptide identifications were similar to those for RKO cells, but that plasma yielded fewer protein identifications. This is consistent with oversampling of the more abundant plasma peptides, which yields relatively few protein identifications.
The oversampling of relatively abundant plasma peptides provides an explanation for the poor representation of low abundance proteins (< 10 ng mL -1 ), even in immunodepleted samples. 20 and indicate that, even with immunodepletion, detection of low abundance proteins is sporadic at best. Untargeted proteomic analyses using current LC-MS/MS platforms thus cannot be expected to discover low abundance, disease-specific biomarkers in plasma. 
